Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial

BACKGROUND: the addition of oligosaccharides to infant formula has been shown to mimic some of the beneficial effects of human milk. The aim of the study was to assess the tolerance and safety of a formula containing an innovative mixture of oligosaccharides in early infancy. METHODOLOGY/PRINCIPAL F...

Descripción completa

Detalles Bibliográficos
Autores principales: Piemontese, Pasqua, Giannì, Maria L., Braegger, Christian P., Chirico, Gaetano, Grüber, Christoph, Riedler, Josef, Arslanoglu, Sertac, van Stuijvenberg, Margriet, Boehm, Günther, Jelinek, Jürgen, Roggero, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227609/
https://www.ncbi.nlm.nih.gov/pubmed/22140499
http://dx.doi.org/10.1371/journal.pone.0028010
_version_ 1782217766842925056
author Piemontese, Pasqua
Giannì, Maria L.
Braegger, Christian P.
Chirico, Gaetano
Grüber, Christoph
Riedler, Josef
Arslanoglu, Sertac
van Stuijvenberg, Margriet
Boehm, Günther
Jelinek, Jürgen
Roggero, Paola
author_facet Piemontese, Pasqua
Giannì, Maria L.
Braegger, Christian P.
Chirico, Gaetano
Grüber, Christoph
Riedler, Josef
Arslanoglu, Sertac
van Stuijvenberg, Margriet
Boehm, Günther
Jelinek, Jürgen
Roggero, Paola
author_sort Piemontese, Pasqua
collection PubMed
description BACKGROUND: the addition of oligosaccharides to infant formula has been shown to mimic some of the beneficial effects of human milk. The aim of the study was to assess the tolerance and safety of a formula containing an innovative mixture of oligosaccharides in early infancy. METHODOLOGY/PRINCIPAL FINDINGS: this study was performed as a multi-center, randomized, double-blind, placebo-controlled trial including healthy term infants. Infants were recruited before the age of 8 weeks, either having started with formula feeding or being fully breast-fed (breastfeeding group). Formula-fed infants were randomized to feeding with a regular formula containing a mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides (prebiotic formula group) or regular formula without oligosaccharides (control formula group). Growth, tolerance and adverse events were assessed at 8, 16, 24 and 52 weeks of age. The prebiotic and control groups showed similar mean weight, length and head circumference, skin fold thicknesses, arm circumference gains and stool frequency at each study point. As far as the anthropometric parameters are concerned, the prebiotic group and the control group did not attain the values shown by the breastfeeding group at any study point. The skin fold thicknesses assessed in the breastfeeding group at 8 weeks were strikingly larger than those in formula fed infants, whereas at 52 weeks were strikingly smaller. The stool consistency in the prebiotic group was softer than in the control group at 8, 16 and 24 weeks (p<0.001) and closer to that of the breastfeeding group. There was no difference in the incidence of adverse events between the two formula groups. CONCLUSIONS: our findings demonstrate the tolerability and the long term safety of a formula containing an innovative mixture of oligosaccharides in a large cohort of healthy infants. TRIAL REGISTRATION: drks-neu.uniklinik-freiburg.de DRKS 00000201
format Online
Article
Text
id pubmed-3227609
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32276092011-12-02 Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial Piemontese, Pasqua Giannì, Maria L. Braegger, Christian P. Chirico, Gaetano Grüber, Christoph Riedler, Josef Arslanoglu, Sertac van Stuijvenberg, Margriet Boehm, Günther Jelinek, Jürgen Roggero, Paola PLoS One Research Article BACKGROUND: the addition of oligosaccharides to infant formula has been shown to mimic some of the beneficial effects of human milk. The aim of the study was to assess the tolerance and safety of a formula containing an innovative mixture of oligosaccharides in early infancy. METHODOLOGY/PRINCIPAL FINDINGS: this study was performed as a multi-center, randomized, double-blind, placebo-controlled trial including healthy term infants. Infants were recruited before the age of 8 weeks, either having started with formula feeding or being fully breast-fed (breastfeeding group). Formula-fed infants were randomized to feeding with a regular formula containing a mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides (prebiotic formula group) or regular formula without oligosaccharides (control formula group). Growth, tolerance and adverse events were assessed at 8, 16, 24 and 52 weeks of age. The prebiotic and control groups showed similar mean weight, length and head circumference, skin fold thicknesses, arm circumference gains and stool frequency at each study point. As far as the anthropometric parameters are concerned, the prebiotic group and the control group did not attain the values shown by the breastfeeding group at any study point. The skin fold thicknesses assessed in the breastfeeding group at 8 weeks were strikingly larger than those in formula fed infants, whereas at 52 weeks were strikingly smaller. The stool consistency in the prebiotic group was softer than in the control group at 8, 16 and 24 weeks (p<0.001) and closer to that of the breastfeeding group. There was no difference in the incidence of adverse events between the two formula groups. CONCLUSIONS: our findings demonstrate the tolerability and the long term safety of a formula containing an innovative mixture of oligosaccharides in a large cohort of healthy infants. TRIAL REGISTRATION: drks-neu.uniklinik-freiburg.de DRKS 00000201 Public Library of Science 2011-11-30 /pmc/articles/PMC3227609/ /pubmed/22140499 http://dx.doi.org/10.1371/journal.pone.0028010 Text en Piemontese et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Piemontese, Pasqua
Giannì, Maria L.
Braegger, Christian P.
Chirico, Gaetano
Grüber, Christoph
Riedler, Josef
Arslanoglu, Sertac
van Stuijvenberg, Margriet
Boehm, Günther
Jelinek, Jürgen
Roggero, Paola
Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial
title Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial
title_full Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial
title_fullStr Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial
title_full_unstemmed Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial
title_short Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an Innovative Prebiotic Formula: A Randomized Controlled Trial
title_sort tolerance and safety evaluation in a large cohort of healthy infants fed an innovative prebiotic formula: a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227609/
https://www.ncbi.nlm.nih.gov/pubmed/22140499
http://dx.doi.org/10.1371/journal.pone.0028010
work_keys_str_mv AT piemontesepasqua toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT giannimarial toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT braeggerchristianp toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT chiricogaetano toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT gruberchristoph toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT riedlerjosef toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT arslanoglusertac toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT vanstuijvenbergmargriet toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT boehmgunther toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT jelinekjurgen toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT roggeropaola toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial
AT toleranceandsafetyevaluationinalargecohortofhealthyinfantsfedaninnovativeprebioticformulaarandomizedcontrolledtrial